ESLA ESTRELLA IMMUNOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, ESTRELLA IMMUNOPHARMA INC reported revenue of n/a, net income of −$2.31M and diluted EPS of −$0.05; for the fiscal year ended December 2025 revenue was n/a.
ESLA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$13.1M, net income −$13.1M (margin n/a), EPS −$0.35
- Fiscal year ended Jun 2024: revenue n/a, gross profit n/a, operating income −$7.31M, net income −$7.31M (margin n/a), EPS −$0.27
- Fiscal year ended Jun 2023: revenue n/a, gross profit n/a, operating income −$11.1M, net income −$11.1M (margin n/a), EPS −$36.35
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$1.57M, net income −$996K (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$249K, net income −$248K (margin n/a), EPS n/a
ESLA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.31M, EPS −$0.05
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.29M, EPS −$0.05
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$613K, EPS −$0.01
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.80M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.54M, EPS −$0.15
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.10M, EPS −$0.06
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.38M, EPS −$0.09
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.95M, EPS −$0.11
- Quarter ended Mar 31, 2024: revenue n/a, net income −$470K, EPS −$0.01
- Quarter ended Dec 31, 2023: revenue n/a, net income −$1.02M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.87M, EPS −$1.78
- Quarter ended Jun 30, 2023: revenue n/a, net income −$76.0K, EPS $22.44
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.74M, EPS −$8.13
- Quarter ended Dec 31, 2022: revenue n/a, net income −$2.76M, EPS −$16.33
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.89M, EPS −$34.33
- Quarter ended Jun 30, 2022: revenue n/a, net income −$360K, EPS −$0.06
- Quarter ended Mar 31, 2022: revenue n/a, net income −$141K, EPS −$0.02
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$136K, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$108K, EPS −$0.99
- Quarter ended Jun 30, 2021: revenue n/a, net income −$3.56K, EPS $0.00
ESLA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.79M, share buybacks n/a
- Fiscal year ended Jun 2024: operating cash flow −$16.1M, share buybacks n/a
- Fiscal year ended Jun 2023: operating cash flow −$1.34M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.04M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$316K, share buybacks n/a
ESLA balance sheet
- Jun 30, 2026: cash $100K, total assets $1.82M, total liabilities $9.26M, shareholders' equity −$7.43M
- Mar 31, 2026: cash n/a, total assets $3.66M, total liabilities $8.93M, shareholders' equity −$5.27M
- Dec 31, 2025: cash $1.38M, total assets $3.18M, total liabilities $13.5M, shareholders' equity −$10.4M
- Sep 30, 2025: cash $1.63M, total assets $3.52M, total liabilities $13.4M, shareholders' equity −$9.84M
- Jun 30, 2025: cash $1.32M, total assets $2.98M, total liabilities $9.08M, shareholders' equity −$6.09M
- Mar 31, 2025: cash $421K, total assets $2.44M, total liabilities $4.28M, shareholders' equity −$1.83M
- Dec 31, 2024: cash $917K, total assets $3.14M, total liabilities $3.00M, shareholders' equity $144K
- Sep 30, 2024: cash $1.80M, total assets $3.74M, total liabilities $2.99M, shareholders' equity $746K
Is ESLA profitable?
No. ESTRELLA IMMUNOPHARMA INC lost $10.0M over the last four quarters.
What is ESLA's EPS?
Diluted earnings per share over the last four quarters were −$0.24; −$0.05 in the latest quarter.